Abstract
Purpose
To investigate changes in urinary PGE2 after ibuprofen treatment in preterm infants with patent ductus arteriosus (PDA).
Methods
Twenty preterm infants with a hemodynamically significant PDA (gestational age, 28.6 ± 2.3 weeks) and 20 controls (gestational age, 30.4 ± 1.5 weeks) were prospectively enrolled at 48–72 h of life. After enrollment, the former underwent conventional ibuprofen-lysine treatment. At 48–72 h (T0) and 108–144 h of life (T1), urine samples were noninvasively collected in both groups to measure urinary PGE2 concentrations (enzyme immunoassay method), and renal function was investigated.
Results
Urinary PGE2 decreased significantly both in ibuprofen-treated patients (66.95 ± 16.78 vs. 27.15 ± 17.92 pg/mL, P < 0.001) and in controls (71.7 ± 16.2 vs. 53.2 ± 18.4 pg/mL, P < 0.001) from T0 to T1. However, urinary PGE2 at T1 was significantly lower (P < 0.001) in the ibuprofen group compared to the control group. Acute renal failure occurred in three ibuprofen-treated patients (15%).
Conclusions
Ibuprofen markedly reduces (59.4%) urinary PGE2 and may alter renal function in the newborn.
Similar content being viewed by others
References
Danilowicz D, Rudolph AM, Hoffman JI (1966) Delayed closure of the ductus arteriosus in premature infants. Pediatrics 37:74–78
Kitterman JA, Edmunds LH Jr, Gregory GA et al (1972) Patent ducts arteriosus in premature infants. Incidence, relation to pulmonary disease and management. N Engl J Med 287:473–477
Clyman RI (2000) Ibuprofen and patent ductus arteriosus. N Engl J Med 343:728–730
Schlondorff D (1993) Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 44:643–653
FitzGerald GA, Patrono C (2001) The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345:433–442
Van Overmeire B, Follens I, Hartmann S et al (1997) Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child 76:179–184
SoRelle R (2000) Ibuprofen as effective as indomethacin for patent ductus arteriosus. Circulation 102:9007–9008
Lago P, Bettiol T, Salvatori S et al (2002) Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. Eur J Pediatr 161:202–207
Pezzati M, Vangi V, Biagiotti R et al (1999) Effect of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr 135:733–738
Van Overmeire B, Smets K, Lecoutere D et al (2000) A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 343:674–681
Gimeno Navarro A, Modesto Alapont V, Morcillo Sopena F et al (2007) Ibuprofen versus indomethacin in the preterm persistent patent ductus arteriosus therapy: review and meta-analysis (in Spanish). An Pediatr (Barc) 67:309–318
Heyman E, Morag I, Batash D et al (2003) Closure of patent ductus arteriosus with oral ibuprofen suspension in premature newborns: a pilot study. Pediatrics 112:354
Guignard JP (2002) The adverse renal effects of prostaglandin-synthesis inhibitors in the newborn rabbit. Semin Perinatol 26:398–405
Cuzzolin L, Fanos V, Pinna B et al (2006) Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions. Pediatr Nephrol 21:931–938
Erdeve O, Sarici SU, Sari E et al (2008) Oral-ibuprofen-induced acute renal failure in a preterm infant. Pediatr Nephrol 23:1565–1567
Bennett A, Villa G (2000) Nimesulide: a nonsteroidal anti-inflammatory drug that preferentially inhibits cyclooxygenase-2, and has various unique pharmacological activities. Expert Opin Pharmacoth 1:277–286
Breyer MD, Zhang Y, Guan Y et al (1998) Regulation of renal function by prostaglandin E receptors. Kidney Int 54:S88–S94
Currie MG, Needleman P (1984) Renal arachidonic acid metabolism. Annu Rev Physiol 46:327–341
Breyer MD, Breyer RM (2000) Prostaglandin receptors: their role in regulating renal function. Curr Opin Nephrol Hypertens 9:23–29
Klahr S, Purkerson ML (1994) The pathophysiology of obstructive nephropathy: the role of vasoactive compounds in the hemodynamic and structural abnormalities of the obstructed kidney. Am J Kidney Dis 23:219–223
Cuzzolin L, Dal Cerè M, Fanos V (2001) NSAID-induced nephrotoxicity from the fetus to the child. Drug Safety 24:9–18
Giniger RP, Buffat C, Millet V et al (2007) Renal effects of ibuprofen for the treatment of patent ductus arteriosus in premature infants. J Matern Fetal Neonatal Med 20:275–283
Catella F, Nowak J, Fitzgerald GA (1986) Measurements of renal and non-renal eicosanoid synthesis. Am J Med 81:23–29
Walker RD, Garin EH (1990) Urinary prostaglandin E2 in patients with vesicoureteral reflux. Child Nephrol Urol 10:18–21
Antonucci R, Cuzzolin L, Arceri A et al (2005) Renal PGE2 in preterm infants: a possible role in the adaptation to extrauterine life. Pediatr Res 58:356
Antonucci R, Cuzzolin L, Arceri A et al (2007) Urinary prostaglandin E2 in the newborn and infant. Prostaglandins Other Lipid Mediat 84:1–13
Skelton R, Evans N, Smythe J (1994) A blinded comparison of clinical and echocardiographic evaluation of the preterm infant for ductus arteriosus. J Paediatr Child Health 30:406–411
Fell JM, Thakkar H, Newman DJ et al (1997) Measurement of albumin and low molecular weight proteins in the urine of newborn infants using a cotton wool ball collection method. Acta Paediatr 86:518–522
Bose CL, Laughon MM (2007) Patent ductus arteriosus: lack of evidence for common treatments. Arch Dis Child Fetal Neonatal Ed 92:F498–F502
Ohlsson A, Walia R, Shah S (2008) Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev (1):CD00348
Thomas RL, Parker GC, Van Overmeire B et al (2005) A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. Eur J Pediatr 164:135–140
Allegaert K, Rayyan M, Anderson BJ (2006) Impact of ibuprofen administration on renal drug clearance in the first weeks of life. Methods Find Exp Clin Pharmacol 28:519–522
Fanos V, Benini D, Verlato G et al (2005) Efficacy and renal tolerability of ibuprofen vs. indomethacin in preterm infants with patent ductus arteriosus. Fundam Clin Pharmacol 19:187–193
Lin YJ, Tsai YJ, Chen JS et al (1995) Renal effects and urinary excretion of prostaglandin following indomethacin therapy in premature infants with patent ductus arteriosus. Acta Pediatr Sin 36:104–107
Agostiniani R, Mariotti P, Cataldi L et al (2002) Role of renal PGE2 in the adaption from foetal to extrauterine life in term and preterm infants. Prostaglandins Leukot Essent Fatty Acids 67:373–377
Ojala R, Ala-Houhala M, Ahonen S et al (2001) Renal follow up of premature infants with and without perinatal indomethacin exposure. Arch Dis Child Fetal Neonatal Ed 84:F28–F33
Rodriguez MM, Gomez AH, Abitbol CL et al (2004) Histomorphometric analysis of postnatal glomerulogenesis in extremely preterm infants. Pediatr Dev Pathol 7:17–25
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Antonucci, R., Cuzzolin, L., Arceri, A. et al. Changes in urinary PGE2 after ibuprofen treatment in preterm infants with patent ductus arteriosus. Eur J Clin Pharmacol 65, 223–230 (2009). https://doi.org/10.1007/s00228-008-0586-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-008-0586-3